Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Berinert Claims Another Part Of The HAE Orphan Market, But May Leave Room

Executive Summary

FDA's approval of CSL Behring's Berinert for treatment of acute attacks of hereditary angioedema specifically mentions only two types of attacks. By approving the C1 esterase inhibitor with a targeted indication, the agency could be leaving open a window in the orphan exclusivity for another approval
Advertisement

Related Content

CSL Behring Launches Co-Pay Assistance Program For Berinert
Different Endpoints Drive HAE Drugs On Road To Approval
Dyax Kalbitor Is Third To Market For HAE, But First For All Acute Attacks
ViroPharma Looks To Cinryze To Drive Sales As Vancocin Faces Likely Generic Competition
Dyax Readies HAE Therapy Kalbitor For Launch; Awareness Precedes Approval
ViroPharma Gets Good News And Bad News On Cinryze From FDA
Dyax Receives “Complete Response” For HAE Drug; REMS Will Be Required
Cinryze Launch Plans Bear Hallmarks Of Successful Orphan Strategies
Cinryze Prophylaxis Approval Leaves Window For HAE Treatment Contenders
Cinryze Prophylaxis Approval Leaves Window For HAE Treatment Contenders

Topics

Advertisement
UsernamePublicRestriction

Register

PS051573

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel